Your browser doesn't support javascript.
loading
Spanish scleroderma risk score (RESCLESCORE) to predict 15-year all-cause mortality in scleroderma patients at the time of diagnosis based on the RESCLE cohort: Derivation and internal validation.
Rubio-Rivas, Manuel; Corbella, Xavier; Guillén-Del-Castillo, Alfredo; Tolosa Vilella, Carles; Colunga Argüelles, Dolores; Argibay, Ana; Vargas Hitos, José Antonio; Todolí Parra, José Antonio; González-Echávarri, Cristina; Ortego-Centeno, Norberto; Trapiella Martínez, Luis; Rodríguez Carballeira, Mónica; Marín Ballvé, Adela; Pla Salas, Xavier; Perales Fraile, Isabel; Chamorro, Antonio-J; Madroñero Vuelta, Ana Belén; Freire, Mayka; Ruiz Muñoz, Manuel; González García, Andrés; Pons Martín Del Campo, Isaac; Sánchez García, María Esther; Bernal Bello, David; Espinosa, Gerard; García Hernández, Francisco José; Sáez Comet, Luis; Ríos Blanco, Juan José; Fernández de la Puebla Giménez, Rafael Ángel; Sánchez Trigo, Sabela; Fonollosa Pla, Vicent; Simeón Aznar, Carmen Pilar.
Afiliación
  • Rubio-Rivas M; Autoimmune Diseases Unit, Department of Internal Medicine, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: mrubio@bellvitgehospital.cat.
  • Corbella X; Autoimmune Diseases Unit, Department of Internal Medicine, Bellvitge University Hospital-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain; Group of Evaluation of Health Determinants and Health Policies, Hestia Chair in Integrated Health and Social Care, Faculty of Medicine and Health Sciences, U
  • Guillén-Del-Castillo A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Tolosa Vilella C; Department of Internal Medicine, Corporación Sanitaria Universitaria Parc Taulí, Sabadell, Barcelona, Spain.
  • Colunga Argüelles D; Department of Internal Medicine, Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain.
  • Argibay A; Unit of Systemic Autoimmune Diseases and Thrombosis, Department of Internal Medicine, Complejo Hospitalario Universitario de Vigo, Vigo, Pontevedra, Spain.
  • Vargas Hitos JA; Department of Internal Medicine, Hospital Universitario Virgen de las Nieves, Granada, Spain.
  • Todolí Parra JA; Department of Internal Medicine, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • González-Echávarri C; Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.
  • Ortego-Centeno N; Inst Invest Biosanitaria Ibs Granada, Department of Internal Medicine, Unit of Systemic Autoimmune Diseases, Department of Medicine, Facultad de Medicina, Hospital Universitario San Cecilio, Granada, Spain.
  • Trapiella Martínez L; Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Hospital de Cabueñes, Gijón, Asturias, Spain.
  • Rodríguez Carballeira M; Department of Internal Medicine, Hospital Universitario Mútua Terrassa, Terrassa, Barcelona, Spain.
  • Marín Ballvé A; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain.
  • Pla Salas X; Unit of Systemic Autoimmune Diseases, Department of Internal Medicine, Consorci Hospitalari de Vic, Vic, Barcelona, Spain.
  • Perales Fraile I; Department of Internal Medicine, Hospital Universitario Rey Juan Carlos, Móstoles, Madrid, Spain.
  • Chamorro AJ; Department of Internal Medicine, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain.
  • Madroñero Vuelta AB; Department of Internal Medicine, Hospital General San Jorge, Huesca, Spain.
  • Freire M; Department of Internal Medicine, Hospital Clínico Universitario de Santiago, Santiago de Compostela, A Coruña, Spain.
  • Ruiz Muñoz M; Department of Internal Medicine, Hospital Universitario Fundación Alcorcón, Alcorcón, Madrid, Spain.
  • González García A; Department of Internal Medicine, Hospital Universitario Ramón y Cajal, Madrid, Spain.
  • Pons Martín Del Campo I; Department of Internal Medicine, Xarxa Assistencial Universitària de Manresa, Manresa, Barcelona, Spain.
  • Sánchez García ME; Department of Internal Medicine, Hospital Universitario Virgen de Valme, Sevilla, Spain.
  • Bernal Bello D; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Fuenlabrada, Madrid, Spain.
  • Espinosa G; Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain.
  • García Hernández FJ; Department of Internal Medicine, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
  • Sáez Comet L; Department of Internal Medicine, Hospital Universitario Miguel Servet, Zaragoza, Spain.
  • Ríos Blanco JJ; Department of Internal Medicine, Hospital Universitario La Paz, Madrid, Spain.
  • Fernández de la Puebla Giménez RÁ; Department of Internal Medicine, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Sánchez Trigo S; Department of Internal Medicine, Complejo Hospitalario Universitario de Ferrol, Ferrol, A Coruña, Spain.
  • Fonollosa Pla V; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
  • Simeón Aznar CP; Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain.
Autoimmun Rev ; 19(5): 102507, 2020 May.
Article en En | MEDLINE | ID: mdl-32194200
ABSTRACT
A few scores predicting the short-term risk of mortality in Systemic sclerosis (SSc) have been reported to date. Our study aimed to create a predictive 15-year all-cause mortality score at the time of the diagnosis of SSc. The study was based on the Spanish Scleroderma Registry (RESCLE). The cohort was split up in derivation (DC) and validation cohort (VC). A multivariate analysis to detect variables related to all-cause mortality within the first 15 years from SSc diagnosis was performed, assigning points to the rounded beta values to create the score (RESCLESCORE). 1935 SSc patients were included. The variables in the final model were as follows age at diagnosis (+2 points > 65 years-old), male gender (+1 point), lcSSc subset (-1 point), mode of onset other than Raynaud's (+1 point), cancer (+1 point) and visceral involvement, such as ILD (+1 point), PAH (+1 point), heart (+1 point) and renal involvement (+2 points). Autoantibodies did not achieve statistical significance in the multivariate analysis. The 3 categories of risk to predict 15-year all-cause mortality at the time of diagnosis were as follows low risk (5% vs. 7%, p = .189), intermediate risk (26.5% vs. 25.5%, p = .911) and high risk (47.8% vs. 59%, p = .316). The AUC was 0.799 (DC) vs. 0.778 (VC) (p = .530). In conclusion, the RESCLESCORE demonstrated an excellent ability to categorize SSc patients at the time of diagnosis in separate 15-year all-cause mortality risk strata at the time of diagnosis.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Causas de Muerte Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Esclerodermia Sistémica / Causas de Muerte Tipo de estudio: Diagnostic_studies / Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies País/Región como asunto: Europa Idioma: En Revista: Autoimmun Rev Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2020 Tipo del documento: Article